On May 19, 2022 Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, reported that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022 (Press release, Theseus Pharmaceuticals, MAY 19, 2022, View Source [SID1234614898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Event: H.C. Wainwright Global Investment Conference
Date / Time: Monday, May 23rd – Thursday, May 26th, 2022, on demand
Format: Virtual Presentation

Event: Jefferies Healthcare Conference
Date / Time: Thursday, June 9th, 2022, at 4:30pm ET
Format: Live Fireside Chat

A live webcast will be available in the Events section of the company’s investor relations website at ir.theseusrx.com and archived for 30 days following the presentations.

Management will also be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Theseus management team should contact their H.C. Wainwright or Jefferies representatives.